Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 16/20 | 0.51 |
| ▸ | CDK1 | P06493 | 8/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CCND3 | P30281 | 1/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4206968 | 0.89 | CDK2 (0.51) | CDK2CDK1CCNE1CCNB2CCNE2 | |
| SCHEMBL4507217 | 0.87 | CDK2 (0.49) | CDK2CDK1CCNE1CCNB2CCNE2 | |
| SCHEMBL4198006 | 0.86 | CDK2 (0.49) | CDK2CDK1CCNE1CCNB2CCNE2 | |
| SCHEMBL4195833 | 0.84 | CDK2 (0.61) | CDK2CDK1CCNE1CCNB2CCNE2 | |
| SCHEMBL4495143 | 0.81 | CDK2 (0.60) | CDK2CDK1CCNE1CCNB2CCNE2 | |
| SCHEMBL4196282 | 0.81 | CDK2 (0.51) | CDK2CDK1CCNE1CCNB2CCNE2 | |
| SCHEMBL3210810 | 0.81 | CDK2 (0.48) | CDK2CDK1CCNE1CCNB2CCNE2 | |
| SCHEMBL3210812 | 0.81 | CDK2 (0.48) | CDK2CDK1CCNE1CCNB2CCNE2 | |
| SCHEMBL3210816 | 0.81 | CDK2 (0.48) | CDK2CDK1CCNE1CCNB2CCNE2 | |
| SCHEMBL4199394 | 0.80 | CDK2 (0.51) | CDK2CDK1CCNE1CCNB2CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | CCNI, MKI67, CDK2 | CDK2 3/4885CDK1 22/4885CCNE1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.